Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabergoline

FDA-approved product (tablet, oral), marketed as Cabergoline, Dostinex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabergoline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypothalamic neoplasm
  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
FDA pharmacologic class
Ergot Derivative FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabergoline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabergoline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

    NCT02271360 · start 2014-04

    Registered record
    Registry ID
    NCT02271360
    Conditions
    Infertility
    Interventions
    Calcium Dobesilate; Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionCalcium Dobesilate; Cabergoline
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

    NCT01915303 · start 2014-03-06

    Registered record
    Registry ID
    NCT01915303
    Conditions
    Cushings Disease
    Interventions
    Pasireotide with or without cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2019-09-04
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCushings Disease
    InterventionPasireotide with or without cabergoline
    PhasePhase 2
    Registry statusTerminated

  • Cabergoline and Coasting to Prevent OHSS

    NCT01984320 · start 2013-10

    Registered record
    Registry ID
    NCT01984320
    Conditions
    OHSS
    Interventions
    ICSI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOHSS
    InterventionICSI
    PhaseNot applicable
    Registry statusCompleted

  • Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

    NCT01535859 · start 2012-04

    Registered record
    Registry ID
    NCT01535859
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Cabergoline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2016-06
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionCabergoline; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Teenagers, Drug Addiction, and Reward and Impulse Control

    NCT01443949 · start 2011-09-11

    Registered record
    Registry ID
    NCT01443949
    Conditions
    Adolescents; Conduct Disorder; Vulnerability to Substance Addicition
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2011-09-11
    Completion
    2013-04-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdolescents; Conduct Disorder; Vulnerability to Substance Addicition
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

    NCT01651364 · start 2011-07

    Registered record
    Registry ID
    NCT01651364
    Conditions
    Cocaine Dependence; Cocaine Abuse; Cocaine Addiction; Substance Abuse
    Interventions
    Placebo; Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-10
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence; Cocaine Abuse; Cocaine Addiction; Substance Abuse
    InterventionPlacebo; Cabergoline
    PhasePhase 1
    Registry statusCompleted

  • Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

    NCT01270711 · start 2010-11

    Registered record
    Registry ID
    NCT01270711
    Conditions
    Parkinson's Disease; Hyperprolactinemia
    Interventions
    Study Drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-02
    Enrolment
    22,014

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Hyperprolactinemia
    InterventionStudy Drug
    PhaseNot recorded
    Registry statusCompleted

  • Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

    NCT01957839 · start 2010-03

    Registered record
    Registry ID
    NCT01957839
    Conditions
    Adverse Reaction to Other Drugs and Medicines
    Interventions
    cabergoline treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-09
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Reaction to Other Drugs and Medicines
    Interventioncabergoline treatment
    PhasePhase 4
    Registry statusCompleted

  • Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program

    NCT01009567 · start 2009-06

    Registered record
    Registry ID
    NCT01009567
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Cabergoline; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-06
    Completion
    2013-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionCabergoline; Control
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ovarian Hyperstimulation Syndrome and Cabergoline

    NCT01569256 · start 2008-03

    Registered record
    Registry ID
    NCT01569256
    Conditions
    Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome
    Interventions
    Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome
    InterventionCabergoline
    PhaseNot applicable
    Registry statusCompleted

  • Acute Application of Pegvisomant and Octreotide in Acromegaly

    NCT00595140 · start 2008-01

    Registered record
    Registry ID
    NCT00595140
    Conditions
    Acromegaly
    Interventions
    pegvisomant; combination with somatostatin analogue octreotide; combination with dopamine agonist cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventionpegvisomant; combination with somatostatin analogue octreotide; combination with dopamine agonist cabergoline
    PhasePhase 4
    Registry statusCompleted

  • Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention

    NCT01530490 · start 2007-08

    Registered record
    Registry ID
    NCT01530490
    Conditions
    Complications Associated With Artificial Fertilization; Disorder of Endocrine Ovary
    Interventions
    Cabergoline and Hydroxyethyl Starch; Hydroxyethyl Starch
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplications Associated With Artificial Fertilization; Disorder of Endocrine Ovary
    InterventionCabergoline and Hydroxyethyl Starch; Hydroxyethyl Starch
    PhaseEarly phase 1
    Registry statusCompleted

  • Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

    NCT00376064 · start 2006-03

    Registered record
    Registry ID
    NCT00376064
    Conditions
    Acromegaly
    Interventions
    Octreotide acetate and cabergoline/Octrotide and Somavert
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionOctreotide acetate and cabergoline/Octrotide and Somavert
    PhasePhase 4
    Registry statusCompleted

  • Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

    NCT01014793 · start 2005-05

    Registered record
    Registry ID
    NCT01014793
    Conditions
    Acromegaly
    Interventions
    cabergoline
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-05
    Completion
    2008-12
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventioncabergoline
    PhaseNot recorded
    Registry statusCompleted

  • Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease

    NCT00153972 · start 2005-02

    Registered record
    Registry ID
    NCT00153972
    Conditions
    Parkinson's Disease
    Interventions
    Cabergoline; Levodopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2009-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionCabergoline; Levodopa
    PhasePhase 4
    Registry statusCompleted